Dengue Vaccine Receives WHO Prequalification
Breakthrough Vaccine Protects Children from Dengue
The World Health Organization (WHO) has granted prequalification to a new vaccine for dengue, a mosquito-borne disease that affects millions of people worldwide. The vaccine, known as Qdenga (TAK-003), is the first and only vaccine to receive WHO prequalification for use in children and adolescents aged 9 to 16 years living in areas with high dengue transmission intensity.
WHO Recommendations
The WHO recommends the use of Qdenga in countries with high dengue transmission intensity, where the disease is a major public health concern. The vaccine is expected to have a significant impact on reducing the burden of dengue, which can cause severe illness and even death.
Vaccine Efficacy
Qdenga is a highly effective vaccine that has been shown to protect children from dengue illness, hospitalizations, and severe dengue 8 out of 10 times. The vaccine is also effective against all four dengue virus serotypes, which means it can protect against all forms of the disease.
Availability
Qdenga has been available for use in children and adolescents in the Philippines since 2022. The vaccine is now available in other countries with high dengue transmission intensity, and it is expected to be available in more countries in the future.
تعليقات